Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
about
CMV in Hematopoietic Stem Cell TransplantationTherapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestThe Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host DiseaseThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAlternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Immunological basis for treatment of graft versus host disease after liver transplant.Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.JAK inhibitors in dermatology: The promise of a new drug class.Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment.Recent advances in hematopoietic stem cell transplantation.Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host DiEvaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors.Ruxolitinib in steroid refractory graft-vs.-host disease: a case reportUpregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.Hematopoietic cell transplantation in primary immunodeficiency - conventional and emerging indications.Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center.Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.New and emerging therapies for acute and chronic graft versus host disease.Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report.The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab.Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.
P2860
Q26740385-411DF7D4-AA7C-4F5F-97AA-A0AFC433457BQ26751959-D37F38FC-106A-4532-9D7E-32C2B2DEAE20Q26777398-0DD470EB-7189-4D83-B9EE-ED401FB7AE84Q28068647-1DC331C4-0D21-4237-97F2-95A4A2C005F4Q28076264-CA8149BF-7B36-4215-8438-187E10E15675Q30252339-EDBF3C20-60DB-430D-A44E-0132096351A1Q33438420-1FB3ABF1-3545-49E1-A2C2-3B824673F13CQ33774610-BC8E1899-2083-4296-85F9-32CBD598FDDBQ37035815-CA65F0F9-2024-4752-B1EF-642496FF8C1EQ37114440-8569A1CA-D0A7-4641-9722-651A80A69A01Q37679267-088AC50B-0715-4660-BB2D-76E74CF9821BQ38712496-90D29A6C-0F91-4778-9859-4EC2F90D1318Q38742863-9253362E-03CC-46BD-922B-06ECC2757F57Q38849186-5A1140B7-8F7C-409D-BBA7-5DD34F5F6BA1Q39002164-6459A511-2DC4-440E-8A51-81475BA3FC85Q39002166-4F1D3C48-ABE8-4B6F-9EA9-AE5829C1AB1EQ39023963-A1318D90-25F3-43A3-9D34-DCD98B0947F2Q39111032-B5B54A00-E786-42A4-B50A-F964FFF3AA57Q39401817-2533FB85-4444-414F-B7AB-00C3AD87848CQ39405882-8FD21FBC-8DC1-48B6-A7F9-6F67FE1FD42FQ40407930-51F0C61B-C2AD-41A0-A29B-EFE49F064E77Q41596288-BA48DC98-E0A0-4114-9501-ED1AD8C1F915Q42255208-3DD4C4B5-BB42-4FD7-A720-C6F6D35E32FDQ42737499-371779F1-B409-4EF6-81A9-4A062F1C5537Q47114304-78152E15-32FB-465B-8B55-D8D900BA9674Q47210347-C52E578E-22A4-4CEA-8EB6-2BF8940EA15DQ47952891-5B4CA216-9108-456E-872C-0F92548A35FEQ48109284-CDDD01D0-3553-4E25-A615-CEB27F13B847Q48139357-7BBAF479-A1C3-4417-A9BF-B4FF98C01D0AQ48146759-A3641AD9-7F6E-4DEB-9FB9-39E74E49E3F8Q48251531-409CEE3B-0BCF-4EFC-8061-1FA131CED756Q48256921-0A6FA434-678B-49F7-966E-DE263AB946EFQ48362201-484E3F82-F153-44BE-ACE2-7872E1328EF1Q49238507-BE9DA2C9-3F62-49FB-B07F-55C6DDBC4736Q49383236-2BAD7302-1651-4534-92F2-354AA8E004E0Q49384876-A9CF682E-A5C7-49D5-BC45-65132F5F5A57Q49679320-508A6400-7B56-4195-853B-799B78CEFA57Q49724160-F7823B89-CC39-4C74-99C5-E7085AF1BB3EQ50025315-EC6638E0-ABD3-47C4-B382-27420EA6BBD9Q50043532-CDBDDA3A-A198-46B0-BD63-965E198E3C4D
P2860
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ruxolitinib in corticosteroid- ...... antation: a multicenter survey
@en
type
label
Ruxolitinib in corticosteroid- ...... antation: a multicenter survey
@en
prefLabel
Ruxolitinib in corticosteroid- ...... antation: a multicenter survey
@en
P2093
P2860
P50
P356
P1433
P1476
Ruxolitinib in corticosteroid- ...... antation: a multicenter survey
@en
P2093
A Burchert
A Neubauer
A Schmitt-Gräff
A Spyridonidis
B R Blazar
P2860
P2888
P304
P356
10.1038/LEU.2015.212
P577
2015-07-31T00:00:00Z
P5875
P6179
1052129890